Experimental Parkinson's Drug by Biogen and Denali Fails in Clinical Trial
STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
Image: Stat
Biogen and Denali Therapeutics announced that their experimental Parkinson's disease drug failed to demonstrate efficacy in a key clinical trial involving 648 participants. The study aimed to target the LRRK2 protein, which has been linked to Parkinson's, but the results mark a setback for this promising therapeutic approach.
- 01The clinical trial involved 648 adults diagnosed with Parkinson's disease.
- 02Participants were randomized to receive either a placebo or a pill targeting the LRRK2 protein.
- 03The LRRK2 gene was linked to a rare inherited form of Parkinson's disease in 2004.
- 04A 2018 study suggested that blocking the LRRK2 protein could benefit all Parkinson's patients.
- 05The trial results represent a significant setback for the therapeutic approach targeting LRRK2.
Advertisement
In-Article Ad
Biogen and Denali Therapeutics reported disappointing results from their clinical trial for an experimental Parkinson's disease drug, which aimed to target the LRRK2 protein. Involving 648 adults with Parkinson's, the study randomized participants to receive either a placebo or the investigational drug. The LRRK2 gene has been associated with a rare inherited form of Parkinson's disease since 2004, and earlier research in 2018 indicated that inhibiting this protein might benefit all patients. However, the failure of this trial poses a significant challenge to the hypothesis that targeting LRRK2 could effectively slow the progression of Parkinson's disease.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think more research should be conducted on LRRK2 as a treatment target for Parkinson's disease?
Connecting to poll...
More about Biogen
Read the original article
Visit the source for the complete story.